Physician profile
Mark Matthew Mims
NPI 1679991475
$6,950.37
in general payments reported to CMS, 2019-2025
18 companies · $2,902 in 2025
The $2,902 reported for 2025 was more than what 93% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $44.80 · 2021: $648 · 2022: $498 · 2023: $990 · 2024: $1,868 · 2025: $2,902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,725 · Consulting Fee: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,724.62 |
| Consulting Fee | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $3,124.54 | 2022-2025 | Avance Nerve Graft, Axoguard Ha+ Nerve Protector, Axoguard Nerve Protector |
| Kerecis Limited | $1,266.59 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Acera Surgical, INC. | $303.85 | 2024-2025 | Restrata Wound Matrix |
| Tela Bio, INC. | $302.57 | 2021-2024 | Ovitex 2s |
| Stryker Corporation | $300.10 | 2021 | |
| Smith+Nephew, INC. | $294.50 | 2022-2025 | Grafix, Stravix |
| Kls-Martin L.P. | $293.49 | 2020-2024 | |
| Polynovo North America LLC | $210.77 | 2022 | |
| Bard Peripheral Vascular, INC. | $145.56 | 2021 | |
| Abbvie INC. | $126.34 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $120.32 | 2025 | |
| Motiva USA, LLC | $111.59 | 2025 | |
| Innovation Technologies INC | $111.58 | 2025 | Irrisept |
| Sientra, INC. | $89.69 | 2022 | |
| Mentor Worldwide LLC | $68.59 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $35.00 | 2023 | Merocel |
| Greer Laboratories, INC. | $24.06 | 2023 | Oralair |
| Allergan, INC. | $21.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.